Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats

[1]  L. Aronne,et al.  Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity , 2008, Diabetes Care.

[2]  Christian Weyer,et al.  Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies , 2008, Proceedings of the National Academy of Sciences.

[3]  C. Weyer,et al.  Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. , 2007, Endocrinology.

[4]  C. Anderson,et al.  Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats. , 2007, American journal of physiology. Endocrinology and metabolism.

[5]  K. Laugero,et al.  Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  P. Wielinga,et al.  Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin , 2007, Physiology & Behavior.

[7]  C. Weyer,et al.  Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. , 2007, American journal of physiology. Endocrinology and metabolism.

[8]  K. Fujioka,et al.  Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. , 2007, The Journal of clinical endocrinology and metabolism.

[9]  C. Anderson,et al.  Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. , 2006, Endocrinology.

[10]  M. W. Schwartz,et al.  Central nervous system control of food intake and body weight , 2006, Nature.

[11]  J. Fernández-López,et al.  Effects of oleoyl-estrone with dexfenfluramine, sibutramine or phentermine on overweight rats. , 2005, European journal of pharmacology.

[12]  S. Doran,et al.  Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes , 2005, Diabetologia.

[13]  P. Shekelle,et al.  Meta-Analysis: Pharmacologic Treatment of Obesity , 2005, Annals of Internal Medicine.

[14]  J. Flier,et al.  The Gut and Energy Balance: Visceral Allies in the Obesity Wars , 2005, Science.

[15]  J. Permert,et al.  Amylin receptor blockade stimulates food intake in rats. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[16]  A. Avenell,et al.  What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. , 2004, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[17]  R. Reidelberger,et al.  Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[18]  T. Wadden,et al.  Obese patients' perceptions of treatment outcomes and the factors that influence them. , 2001, Archives of internal medicine.

[19]  L. Aronne,et al.  Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. , 2001, Metabolism: clinical and experimental.

[20]  E. Scharrer,et al.  The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats , 2001, International Journal of Obesity.

[21]  T. Adrian,et al.  Effects of long-term infusion of anorexic concentrations of islet amyloid polypeptide on neurotransmitters and neuropeptides in rat brain , 2000, Brain Research.

[22]  B. Levin,et al.  Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[23]  S. Woods,et al.  Central nervous system control of food intake , 2000, Nature.

[24]  E. Scharrer,et al.  Amylin receptors mediate the anorectic action of salmon calcitonin (sCT) , 2000, Peptides.

[25]  S. Woods,et al.  Amylin: a novel action in the brain to reduce body weight. , 2000, Endocrinology.

[26]  S. Woods,et al.  Amylin and insulin interact to reduce food intake in rats. , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[27]  N. Rowland,et al.  Anorectic efficacy of the fenfluramine/phentermine combination in rats: additivity or synergy? , 1999, European journal of pharmacology.

[28]  N. Geary,et al.  Behaviorally specific inhibition of sham feeding by amylin , 1998, Peptides.

[29]  H. Jackson,et al.  Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. , 1998, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[30]  A. Young,et al.  Synergy between amylin and cholecystokinin for inhibition of food intake in mice , 1998, Physiology & Behavior.

[31]  N. Rowland,et al.  Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in rats , 1998, Psychopharmacology.

[32]  B. Balkan,et al.  Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. , 1997, The American journal of physiology.

[33]  M. Stock,et al.  Sibutramine: a review of the pharmacology of a novel anti-obesity agent. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[34]  Andrew A. Young,et al.  Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin , 1996 .

[35]  J. Fischer,et al.  Amylin increases transport of tyrosine and tryptophan into the brain , 1992, Brain Research.

[36]  J. Fischer,et al.  Anorexia following the intrahypothalamic administration of amylin , 1991, Brain Research.

[37]  R. Foltin.  Effects of anorectic drugs on the topography of feeding behavior in baboons. , 1989, The Journal of pharmacology and experimental therapeutics.

[38]  J. Arch.  The contribution of increased thermogenesis to the effect of anorectic drugs on body composition in mice. , 1981, The American journal of clinical nutrition.

[39]  T. Rink,et al.  Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat. , 1993, Life sciences.

[40]  A. Young,et al.  No measurable effect of amylin on lipolysis in either white or brown isolated adipocytes from rats , 1993 .

[41]  R. Samanin.  Central mechanisms of anorectic drugs , 1981 .